TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02274285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib Combined vaccine
Description: 0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV vaccine and Hib vaccine
Description: 0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib Combined vaccine
Description: 0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart
Study: NCT01721499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: weekly group and individual skills training to improve self control and decrease stress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: weekly group and individual skills training to improve self control and decrease stress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Study: NCT05425563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Expectancy Cues
Description: Participants are presented with a social cue that represents how previous participants responded to the upcoming somatic pain stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vicarious Pain Expectancy Cues
Description: Participants are presented with a social cue that represents how previous participants responded to the upcoming vicarious pain stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Effort Expectancy Cues
Description: Participants are presented with a social cue that represents how previous participants responded to the upcoming cognitive effort stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
Study: NCT04499729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntelliCare
Description: IntelliCare provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as usual in the Rush Collaborative Care service
Study: NCT01474798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RA-18C3
Description: For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.~For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection.
Study: NCT02786030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach education training
Description: Printed copies of the patient management tool (PMT) and outreach education training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No outreach education training
Description: Printed copies of the patient management tool (PMT) without outreach education training
Study: NCT00756080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citrulline
Description: 0.06 G/kg three times/day during 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
Study: NCT04046211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Gas exposure for 24, 48 or 72 hours via high flow nasal cannula.
Study: NCT03928197

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tilt Test
Description: Volunteers need to lay down for 15 minutes and afterwards stand up for 15 minutes

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tilt Test
Description: Volunteers need to lay down for 15 minutes and afterwards stand up for 15 minutes
Study: NCT00060359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00275132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Tarceva (OSI-774, erlotinib) PO 150 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo PO daily
Study: NCT00913458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Study: NCT05506228

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT00875134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal prompt
Description: Patient hears a voice recording

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Stimulus
Description: Patient receives either a skin stimulus
Study: NCT02998632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mineralized plasmatic matrix for bone augmentation
Description: Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone for bone augmentation
Description: Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
Study: NCT01765309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral mastectomy with reconstruction
Description: In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
Study: NCT02113254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corn zeaxanthin
Description: The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
Study: NCT04175119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual attention/perception tasks in healthy participants
Description: The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation
Study: NCT04705493

Intervention type: OTHER
Intervention: fluid resuscitation with crystalloid
Description: give two-volume of fluids initial 250ml then another 250 ml
Study: NCT00586092

Intervention type: DRUG
Group type: OTHER
Intervention: bevacizumab, ABT-510
Description: * Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID\*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days\*~* Stage 2 (RPTD) ABT-510: X mg SC BID\*\*, bevacizumab: Y mg/kg IV every 14 days\*\*~  * Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~    * \*Both agents begin on Day 1 of Cycle 1.~      * \*\*At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination.
Study: NCT00992589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium 5 mg
Description: Rabeprazole Sodium 5 mg capsules once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium 10 mg
Description: Rabeprazole Sodium 10 mg capsules once daily in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules once daily in the morning.
Study: NCT04368078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus Lenvatinib
Description: Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle. Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, oral at least 38 days of each 6 weeks cycle, day 2.~Number of cycle: until progression or unacceptable toxicity events develop
Study: NCT00915499

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VPAP Adapt SV
Description: Comparison of ASV and CPAP modes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VPAP Adapt SV
Description: Comparison of ASV and CPAP modes
Study: NCT03360864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program
Description: Patient will participate to a education program.
Study: NCT02074891

Intervention type: DRUG
Intervention: coformulated TDF/FTC
Description: Daily oral dose of coformulated TDF/FTC
Study: NCT01542424

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Prescribed at the discretion of the physician

Intervention type: DRUG
Intervention: insulin detemir
Description: Prescribed at the discretion of the physician
Study: NCT00965965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New colorectal cancer screening patient education document
Description: The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional colorectal cancer screening education document
Description: The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
Study: NCT00329849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY-CRM conjugate vaccine
Description: MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ACWY-PS polysaccharide vaccine
Description: MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
Study: NCT02332707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
Description: Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
Description: Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
Description: Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
Description: Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
Study: NCT00435045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin
Description: Lovaza + atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin + placebo
Study: NCT01141062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips MR-guided HIFU
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
Study: NCT03469778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Therapy
Description: Robotic Therapy
Study: NCT04311593

Intervention type: DIAGNOSTIC_TEST
Intervention: CD4, CD19, CD38, CD56 and CD11b
Description: measuring CD markers by flowcytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: CD4, CD19, CD38, CD56 and CD11b
Description: measuring CD markers by flowcytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: CD4, CD19, CD38, CD56 and CD11b
Description: measuring CD markers by flowcytometry
Study: NCT02361645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% eyedrops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5% eyedrops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09% eyedrops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1% eyedrops
Study: NCT01001702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
Study: NCT00988247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Aerosol
Description: Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
Study: NCT02243228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Study: NCT02633371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin 3% gel
Study: NCT01255774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: An open-label, study of intravitreally administered ranibizumab
Study: NCT02557178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coaching
Description: Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
Study: NCT00434967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: 32 mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 25 mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 25 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan/HCT 32/25 mg
Study: NCT00976144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
Study: NCT01989221

Intervention type: DRUG
Group type: OTHER
Intervention: Sancuso®
Description: Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
Study: NCT04111614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib tablet
Description: Single dose of tofacitinib 5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib tablet
Description: Single dose of tofacitinib 5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib Oral Solution
Description: Single 5 mL dose of tofacitinib oral solution (1 mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib Oral Solution
Description: Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
Study: NCT00670826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vitalHEAT vH2 Temperature Management System
Description: The vH2 system utilizes a combination of localized heat and vacuum application to one hand \& forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arizant Healthcare Bair Hugger Temperature Management System
Description: The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
Study: NCT00462787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Study: NCT03743077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training including inspiratory muscle training
Description: Volunteers will participate in the the spinal mobility fitness training program for a frequency of one to 3 times a week with pre and post tests including four objective measures of function (timed t-shirt test, timed transfer test, four direction reach test and trunk test of strength) and a pre and post subjective interview. In addition to the program consenting volunteers will perform inspiratory muscle training as a home program and submit weekly diaries tracking their training. The inspiratory muscle trainer by Respironics provides specific pressure for inspiratory muscle strength and endurance, regardless of how quickly or slowly patients breathe. It exercises respiratory muscles and improves breathing. It Improves muscle strength and is easy to use.
Study: NCT04355585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: 1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: 1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
Study: NCT00462787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study: NCT04355585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
Study: NCT01552798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: 2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
Study: NCT03294577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D5W Placebo
Description: Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Study: NCT01791959

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: synbiotic
Description: 2 symbiotics capsules per day for 28 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 Maltodexterin capsules as a placebo per day for 28 weeks
Study: NCT01097928

Intervention type: PROCEDURE
Intervention: Catheter directed debulking of Pulmonary Embolus
Description: A catheter will be used to break up the pulmonary embolism
Study: NCT03457961

Intervention type: DRUG
Intervention: Perampanel
Description: This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
Study: NCT03377920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-check Dial device (Clement Clarke International Ltd, Harlow, UK)
Description: * pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up).~* 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's